Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings)
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ: ITCI) has received mixed evaluations from 9 analysts over the past three months, with a majority being bullish. The average 12-month price target has increased to $99.0. The company has shown significant revenue growth but faces challenges in profitability and returns.
August 07, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies has received mixed analyst ratings, with a majority being bullish. The average 12-month price target has increased to $99.0, indicating positive sentiment. The company has shown strong revenue growth but faces challenges in profitability and returns.
The majority of analysts are bullish on ITCI, and the average price target has increased, indicating positive sentiment. However, the company faces challenges in profitability and returns, which may temper the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100